Cancer Therapy Toxicities - Case Study - Falling Ejection Fraction on HER2 Therapy

A 46-year-old florist comes in for a routine surveillance echocardiogram, feeling well. Her ejection fraction has fallen from 62 percent to 44. Now reason it out. A resident presents to an attending on teaching rounds, working through cancer therapy toxicity one patient at a time rather than one table at a time. What you'll learn: • How to read a surveillance echocardiogram: why the pre-treatment ejection fraction is what makes today's number interpretable, and why a normal exam is the rule rather than reassurance • Why drug sequence matters - four months of an anthracycline spends the muscle and repair reserve before trastuzumab removes the pathway the survivors depend on • Demolition versus unplugging: cumulative, dose-dependent myofibril loss against a blocked HER2 survival signal with near-normal histology and common recovery • Four unfold cases - a swim coach with bleomycin pulmonary fibrosis, a locksmith with cisplatin neuropathy and ototoxicity, a piano tuner with cytarabine cerebellar toxicity, and an orchard manager with capecitabine hand-foot syndrome • The pre-treatment checks and the rescue agents, each justified from chemistry: ejection fraction, PFTs, IV saline, Mesna, urinary alkalinisation, glucarpidase, methylene blue and thiamine Key takeaway: Ask why this organ and not another - the cell's biology, and sometimes a single transporter, chooses the target long before the drug does. ⏱ Chapters: 0:00 The surveillance finding: ejection fraction 62 to 44 3:11 Why the heart: anthracycline versus trastuzumab 6:01 Unfold cases: bleomycin lung and cisplatin neuropathy 8:30 Assessment, prevention and the rescue agents 12:23 Trajectory, hand-foot syndrome and teaching pearls Part of Teaching Service — Hospital Rounds: education for residents and advanced practice providers. For clinician and trainee education only. Not medical advice; verify against current guidelines and institutional protocols before applying to patient care. #Cardiotoxicity #Chemotherapy #Oncology #CaseStudy #Trastuzumab #Anthracycline #InternalMedicine #MedicalEducation #Cardiology #ResidentEducation